Prognostic value of concomitant resection of extrahepatic disease in patients with liver metastases of colorectal origin

Aoki, Taku; Umekita, Nobutaka; Tanaka, Soichi; Noda, Kazumasa; Warabi, Masahiro; Kitamura, Masatsugu

doi:10.1016/j.surg.2008.02.004

Cited by 34 publications

(27 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data are in concordance with previous reports on surgical treatment of multiple sites MCC; the presence of multiple extra-hepatic site and more than five liver metastasis were the only two variables correlated with survival [14] . More recently a tumor load-based nomogram have been proposed for patients with potentially resectable synchronous peritoneal and liver metastases [20] .…”

Section: Patient Selection For Cs + Hipec + Lrsupporting

confidence: 93%

“…Although the role of surgery in presence of multiple sites of MCC is almost un-explored, the combined and/ or sequential resection of liver, lymph nodes, lung metastases in various combinations has been tested with encouraging outcomes in very selected cases [11] . Radical surgery for concomitant liver and extra-hepatic MCC has shown results that seem comparable to those obtained for isolated hepatic metastases [12][13][14][15] . For colorectal liver metastases (LM), radical surgery offers a chance of cure in at least 17% of patients and liver resection (LR) has become the standard treatment for patients with resectable disease [16] .…”

Section: Introductionmentioning

confidence: 68%

“…Although, in one study, patients who underwent liver and extra-hepatic disease resection seem to have a worse prognosis [14] , a single center experience reported a 28% 5-year survival rate in patients who underwent an R0 resection of extrahepatic disease simultaneously with hepatectomy for colorectal liver metastasis [12] . Unexpected peritoneal disease at time of planned liver resection was estimated in 3% of cases in a large single center experience [21] .…”

Section: Surgery For Peritoneal and Liver MCCmentioning

confidence: 98%

See 2 more Smart Citations

Roles of dysregulated Notch pathway and small DNA tumor viruses in cancer initiation and progression

Clementz¹,

Rizzo²,

Martini³

et al. 2015

J Cancer Metastasis Treat

View full text Add to dashboard Cite

How to cite this article: Sommariva A. Treatment of liver metastases in patients selected for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis. J Cancer Metastasis Treat 2017;3:362-7. Cytoreductive surgery (CS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have gained increasing consensus in treatment of peritoneal carcinomatosis from colorectal cancer. The presence of liver metastases is generally considered a contraindication for CS + HIPEC, as hepatic involvement no longer represents a loco-regional aspect of disease. Despite this, liver resection (LR) has been tested in selected cases in combination with CS + HIPEC for treatment of peritoneal carcinomatosis with liver metastasis. Relevant studies on this topic were identified through a search in the electronic PubMed database, using the appropriate keywords. CS + HIPEC + LR allows similar outcomes in terms of survival and morbidity with respect to CS + HIPEC, especially in patients with low tumor load. CS + HIPEC + LR represents a reasonable approach for patients with peritoneal carcinomatosis and liver metastases from colorectal cancer. Patients should be selected in high volume tertiary centres, preferably in the context of a prospective trial. Quick Key words:Colorectal cancer, peritoneal carcinomatosis, liver metastases, hyperthermic intraperitoneal chemotherapy, liver resection ABSTRACTArticle history:

show abstract

Section: Patient Selection For Cs + Hipec + Lrsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 68%

Section: Surgery For Peritoneal and Liver MCCmentioning

confidence: 98%

See 1 more Smart Citation

Roles of dysregulated Notch pathway and small DNA tumor viruses in cancer initiation and progression

Clementz¹,

Rizzo²,

Martini³

et al. 2015

J Cancer Metastasis Treat

View full text Add to dashboard Cite

show abstract

“…Resection of metastatic colorectal cancer involving the spleen has been described previously as the only known site of residual disease with disease-free and overall survival of up to 7 years [24,31] in conjunction with resection of other sites of metastatic disease [32].…”

Section: Discussionmentioning

confidence: 99%

Splenectomy for non-haematological metastatic malignant disease

Gatenby

Mudan

Wotherspoon

2011

Langenbecks Arch Surg

View full text Add to dashboard Cite

More favorable outcomes were seen in patients with metachronous disease. There was a trend to improved outcome in ovarian and colorectal primaries over malignant melanoma. It is postulated that improved outcome may be seen in patients for whom there were effective adjuvant chemotherapeutic options, low probability of other metastatic disease and less aggressive tumour biology. However, frequently the presentation is indicative of aggressive widespread disease with a poor prognosis.

show abstract

“…There are few series of patients with CLM and EHD [200][201][202][203][204] . EHD was diagnosed preoperatively just in 40-65% of the cases.…”

Section: Associated Extrahepatic Disease (Ehd)mentioning

confidence: 99%

Metastatic lesions to the liver: Surgical indications and techniques

Tejedor¹,

Serrablo²

2013

JST

View full text Add to dashboard Cite

Background: Although there is an established agreement on the advantage of liver resection for metastatic colorectal and neuroendocrine tumours, the role of hepatic surgery in patients with liver metastases from non-colorectal and non-neuroendocrine carcinoma is not well defined. In recent years, despite the poor results, liver metastases suitable for surgery have been treated with resection. The results reported in recent studies support a developing trend toward surgery in this setting. Also, as there are no data that in fact suggest the utility of alternative treatments for these lesions, the role of surgery is reinforced. Methods:A systematic search of English and non-English literature using MEDLINE on the outcomes of patients after surgical treatment of liver metastases from different solid tumours was undertaken. A summary of current surgical techniques used to improve their resectability has been added.Results: All papers reporting median survival and 5-year survival have been selected and presented in tables for most of the primary tumours reviewed. Conclusions:Apart from patients with colorectal and neuroendocrine tumours, liver resection may offer a significative survival advantage in selected patients, mainly those with metastases coming from breast, gastrointestinal stromal tumours, testis, ovary and kidney.

show abstract

Prognostic value of concomitant resection of extrahepatic disease in patients with liver metastases of colorectal origin

Cited by 34 publications

References 42 publications

Roles of dysregulated Notch pathway and small DNA tumor viruses in cancer initiation and progression

Roles of dysregulated Notch pathway and small DNA tumor viruses in cancer initiation and progression

Splenectomy for non-haematological metastatic malignant disease

Metastatic lesions to the liver: Surgical indications and techniques

Contact Info

Product

Resources

About